Malotilate

Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM) . Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes[1][2].

Product Specifications

CAS Number

[59937-28-9]

Product Name Alternative

NKK 105

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Lipoxygenase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/malotilate.html

Purity

99.47

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(OC(C)C)/C(C(OC(C)C)=O)=C1SC=CS\1

Molecular Formula

C12H16O4S2

Molecular Weight

288.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Matsuda Y, et al. Effects of malotilate on alcoholic liver injury in rats. Alcohol Clin Exp Res. 1988;12 (5) :665-670.|[2]Vermeer MA, Wilson JH, Zijlstra FJ, Vincent JE. Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells. Agents Actions. 1989;26 (1-2) :252-253.|[3]Poeschl A, et al. Malotilate reduces collagen synthesis and cell migration activity of fibroblasts in vitro. Biochem Pharmacol. 1987;36 (22) :3957-3963.|[4]Zijlstra FJ, et al. Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells. Eur J Pharmacol. 1989;159 (3) :291-295.|[5]Wakasugi J, et al. Action of malotilate on reduced serum cholesterol level in rats with carbon tetrachloride-induced liver damage. Jpn J Pharmacol. 1985;38 (4) :391-401.